Cytokines, acute-phase proteins, and hormones: IL-1 and TNF-α production in contact-mediated activation of monocytes by T lymphocytes

Annals of the New York Academy of Sciences

Volumn 966, Issue , 2002, Pages 464-473

  Burger, Danielle ^a   Dayer, Jean Michel ^a  

^a Faculty of Medicine   (Switzerland)

Author keywords

Acute phase proteins; Cytokines; IL 1; Monocytes; T lymphocytes; TNF

Indexed keywords

ACUTE PHASE PROTEIN; ANDROGEN; CYTOKINE; ESTRADIOL; ESTROGEN; HORMONE; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 4; TESTOSTERONE; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

CONFERENCE PAPER; CYTOKINE PRODUCTION; HOMEOSTASIS; HORMONAL REGULATION; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IMMUNE RESPONSE; IMMUNITY; INFLAMMATION; LYMPHOCYTE ACTIVATION; MONOCYTE; T LYMPHOCYTE;

EID: 0036308243     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2002.tb04248.x     Document Type: Conference Paper

References (73)

1. Inhibitory cytokines and cytokine inhibitors
2. Cytokines and growth factors
3. Cytokine inhibitors
4. The inhibitory activity of human interleukin-1 receptor antagonist is enhanced by type II interleukin-1 soluble receptor and hindered by type I interleukin-1 soluble receptor
5. IL-1Ra
6. Decoy receptors: A strategy to regulate inflammatory cytokines and chemokines
7. T-cell subsets (Th1 versus Th2)
8. IFN-beta inhibits the ability of T lymphocytes to induce TNF-alpha and IL-1beta production in monocytes upon direct cell-cell contact
9. Fibroblast function and fibrosis
10. Cytokine pathways and joint inflammation in rheumatoid arthritis
11. Differential aspects of cytokines in the immunopathology of multiple sclerosis
12. TNFalpha promotes proliferation of oligodendrocyte progenitors and remyelination
13. Cytokine abnormalities in human lupus
14. The role of the endothelium in systemic vasculitis
15. Elevated serum levels of TNF-soluble receptors in patients with positive anti-neutrophil cytoplasmic antibodies
16. The role of inflammation in vascular diseases
17. Correlation of plasma interleukin 1 levels with disease activity in rheumatoid arthritis
18. Tumour necrosis factor in serum and synovial fluid of patients with active and severe rheumatoid arthritis
19. Determination of cytokines in synovial fluids: Correlation with diagnosis and histomorphological characteristics of synovial tissue
20. Cytokine profile in systemic lupus erythematosus, rheumatoid arthritis, and other rheumatic diseases
21. Tumor necrosis factor in the serum of patients with systemic lupus erythematosus
22. Cytokine production (IL-6 and TNF-alpha) in whole blood cell cultures of patients with systemic lupus erythematosus
23. Balance of IL-1 receptor antagonist/IL-1β in rheumatoid synovium and its regulation by IL-4 and IL-10
24. Cytokines and the chronic inflammation of rheumatic disease
25. Quantitative analysis of cytokine gene expression in rheumatoid arthritis
26. Interleukin-1 (IL-1) receptor antagonist, soluble tumor necrosis factor receptors, IL-1 beta, and IL-8: Markers of remission in rheumatoid arthritis during treatment with methotrexate
27. Elevated serum levels of interleukin-1 receptor antagonist in polymyositis/dermatomyositis: A biologic marker of disease activity with a possible role in the lack of acute-phase protein response
28. Interleukin-1 receptor antagonist in patients with active systemic lupus erythematosus: Enhanced production by monocytes and correlation with disease activity
29. Elevated TNF receptor plasma concentrations in patients with rheumatoid arthritis
30. Correlation between serum levels of soluble tumor necrosis factor receptor and disease activity in systemic lupus erythematosus
31. Effects on leukocytes after injection of tumor necrosis factor into healthy humans
32. Soluble receptors for tumor necrosis factor and interleukin-2 in serum and synovial fluid of patients with rheumatoid arthritis, reactive arthritis and osteoarthritis
33. Soluble tumor necrosis factor receptors in human inflammatory synovial fluids
34. Cytokine autoantibodies in rheumatoid arthritis
35. Increased incidence of neutralizing autoantibodies against interleukin-1 alpha (IL-1 alpha) in nondestructive chronic polyarthritis
36. Participation of monocyte-macrophages and lymphocytes in the production of a factor that stimulates collagenase and prostaglandin release by rheumatoid synovial cells
37. Cell-cell interactions and collagenase production
38. IFN-gamma and 1,25(OH)2D3 induce on THP-1 cells distinct patterns of cell surface antigen expression, cytokine production, and responsiveness to contact with activated T cells
39. Cell surface glycoproteins expressed on activated human T-cells induce production of interleukin-1 beta by monocytic cells: A possible role of CD69
40. Interleukin-15 mediates T cell-dependent regulation of tumor necrosis factor-alpha production in rheumatoid arthritis
41. Cytokine stimulation of T lymphocytes regulates their capacity to induce monocyte production of tumor necrosis factor-alpha, but not interleukin-10: Possible relevance to pathophysiology of rheumatoid arthritis
42. Lymphocyte activation gene-3, a MHC class II ligand expressed on activated T cells, stimulates TNF-alpha and IL-alpha production by monocytes and dendritic cells
43. Cell contact-mediated signaling of monocytes by stimulated T cells: A major pathway for cytokine induction
44. Clinical improvement as reflected in measures of function and health-related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: Sensitivity and relative efficiency to detect a treatment effect in a twelve-month, placebo-controlled trial
45. Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: Results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis
46. Treatment of multiple sclerosis with interferon beta
47. Interferon beta in the treatment of multiple sclerosis: Mechanisms of action
48. Exposure of T lymphocytes to leflunomide but not to dexamethasone favors the production by monocytic cells of interleukin-1 receptor antagonist and the tissue-inhibitor of metalloproteinases-1 over that of interleukin-1 beta and metalloproteinases
49. Interferon-beta not only inhibits interleukin-1-beta and tumor necrosis factor-alpha but stimulates interleukin-1 receptor antagonist production in human peripheral blood mononuclear cells
50. Apolipoprotein function in health and disease: Insights from natural mutations
51. Apolipoprotein A-I inhibits the production of interleukin-1 beta and tumor necrosis factor-alpha by blocking contact-mediated activation of monocytes by T lymphocytes
52. Acute-phase proteins and other systemic responses to inflammation
53. Lipid profiles in untreated patients with rheumatoid arthritis
54. Analysis of changes in acute-phase plasma proteins in an acute inflammatory response and in rheumatoid arthritis using two-dimensional gel electrophoresis
55. Serum total, HDL, LDL cholesterol, and triglyceride levels in patients with rheumatoid arthritis
56. Association of the inflammatory state in active juvenile rheumatoid arthritis with hypo-high-density lipoproteinemia and reduced lipoprotein-associated platelet-activating factor acetylhydrolase activity
57. Low levels of total cholesterol, high-density lipoprotein, and apolipoprotein AI in association with anticardiolopin antibodies in patients with SLE
58. Frequency of antibodies to the cholesterol transport protein apolipoprotein A1 in patients with SLE
59. Interferon beta 1a therapy changes lipoprotein metabolism in patients with multiple sclerosis
60. The inflamed plaque: Cytokine production and cellular cholesterol balance in the vessel wall
61. A definition of initial, fatty streak, and intermediate lesions of atherosclerosis: A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association
62. Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein A-I in mice
63. Apolipoprotein AI transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice
64. Inflammation-mediated rheumatic diseases and atherosclerosis
65. The cascade of inflammatory cytokines regulating synthesis of acute phase proteins
66. Effects of sex hormones on production of interleukin-1 by human peripheral monocytes
67. The effect of 17beta-estradiol on production of cytokines in cultures of peripheral blood
68. Progesterone and estradiol modulate interleukin-1 beta messenger ribonucleic acid levels in cultured human peripheral monocytes
69. Sex, plasma lipoproteins, and atherosclerosis: Prevailing assumptions and outstanding questions
70. Sex hormones and coronary disease: A review of the clinical studies
71. Sex hormones, lipoproteins, and vascular reactivity
72. A tale of two diseases: Atherosclerosis and rheumatoid arthritis
73. Hormonal regulation of apolipoprotein AI